← Leaderboards
Klaus Van Leyen
Massachusetts General Hospital
$8,399,290
Attributed
$8,399,290
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $746.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,399,290 · 7
By mechanism
R01$4,592,958 · 2
UH3$1,331,128 · 1
U01$993,388 · 1
R21$575,797 · 1
UG3$497,644 · 1
R61$408,375 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Ciprian Catana$19,814,726
- Matthias Schmand$1,257,827
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelNeuronsIschemiaNeuron LossArachidonate 15-LipoxygenaseOxidative StressInfarctionBrainLeadReperfusion TherapyInjuryStrokeInhibitor/AntagonistBlood - Brain Barrier AnatomyCerebral IschemiaCellsIn VitroEnzymesEdemaBrain InjuriesNovel TherapeuticsLipoxygenase InhibitorsCell DeathNeurologic
Grant awards (23)
Testing the Lipoxygenase Inhibitor BPN - 27332 as acute phase stroke treatment in the SPAN network$225,729
U01 · FY2025 · NS · contact PI
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network$116,883
U01 · FY2025 · NS · contact PI
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network$312,234
U01 · FY2024 · NS · contact PI
A Novel Neuroprotectant to Reduce Ischemic Injury$408,375
R61 · FY2023 · NS · contact PI
Testing the Lipoxygenase Inhibitor BPN-27332 as Acute Phase Stroke Treatment in the SPAN Network$338,542
U01 · FY2023 · NS · contact PI
Development of human 12/15-lipoxygenase therapeutics for stroke$661,539
UH3 · FY2020 · NS · contact PI
Development of human 12/15-lipoxygenase therapeutics for stroke$669,589
UH3 · FY2019 · NS · contact PI
Development of human 12/15-lipoxygenase therapeutics for stroke$497,644
UG3 · FY2018 · NS · contact PI
12/15-Lipoxygenase and neurovascular damage following cardiac arrest$380,625
R01 · FY2015 · NS · contact PI
Novel 12/15 lipoxygenase inhibitors for the treatment of stroke$273,149
R21 · FY2015 · NS · contact PI
12/15-Lipoxygenase and neurovascular damage following cardiac arrest$376,820
R01 · FY2014 · NS · contact PI
Novel 12/15 lipoxygenase inhibitors for the treatment of stroke$302,648
R21 · FY2014 · NS · contact PI
12/15-Lipoxygenase and neurovascular damage following cardiac arrest$361,055
R01 · FY2013 · NS · contact PI
Effects of Semaphorin 3A on Stroke Recovery$330,107
R01 · FY2013 · NS · contact PI
12/15-Lipoxygenase and neurovascular damage following cardiac arrest$374,850
R01 · FY2012 · NS · contact PI
Effects of Semaphorin 3A on Stroke Recovery$342,400
R01 · FY2012 · NS · contact PI
12/15-Lipoxygenase and neurovascular damage following cardiac arrest$376,716
R01 · FY2011 · NS · contact PI
Effects of Semaphorin 3A on Stroke Recovery$344,640
R01 · FY2011 · NS · contact PI
12-Lipoxygenase and Ischemic Brain Cell Death$335,478
R01 · FY2009 · NS · contact PI
12-Lipoxygenase and Ischemic Brain Cell Death$335,478
R01 · FY2008 · NS · contact PI
12-Lipoxygenase and Ischemic Brain Cell Death$335,478
R01 · FY2007 · NS · contact PI
12-Lipoxygenase and Ischemic Brain Cell Death$345,498
R01 · FY2006 · NS · contact PI
12-Lipoxygenase and Ischemic Brain Cell Death$353,813
R01 · FY2005 · NS